Lixte CFO swaps 50K options for stock units

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Rhea-AI Filing Summary

LIXTE BIOTECHNOLOGY HOLDINGS, INC. Chief Financial Officer Peter Stazzone restructured his equity compensation on April 15, 2026. He agreed to cancel 50,000 stock options with a $4.45 exercise price in exchange for 50,000 restricted stock units granted the same day.

Each RSU represents a contingent right to receive one share of common stock, and all 50,000 RSUs vested immediately upon grant, leaving him with 50,000 shares of common stock held directly after the transactions. No open‑market buying or selling occurred; these were compensation-related adjustments between the executive and the company.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Stazzone Peter

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Disposition	Options to Purchase Common Stock	50,000	$0.00	$0.00
Grant/Award	Common Stock	50,000	$0.00	$0.00

Holdings After Transaction: Options to Purchase Common Stock — 0 contracts (Direct); Common Stock — 50,000 shares (Direct)

Footnotes (2)

1. F1. On April 15, 2026, the Issuer canceled, pursuant to that certain Stock Option Cancellation Agreement dated April 15, 2026 between the Issuer and the Reporting Person, the 50,000 options (the "Options") granted to the Reporting Person on September 1, 2025. In exchange for the Options, the Reporting Person received 50,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable award agreement dated April 15, 2026 and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 50,000 RSUs vest immediately upon grant.
2. F2. The canceled Options provided for vesting 25% on September 1,2025, 25% on December 15,2025, 25% on March 15,2026, and 25% on June 15,2026.

Key Figures

Options canceled: 50,000 options RSUs granted: 50,000 RSUs Exercise price of canceled options: $4.45 per share +2 more

5 metrics

Options canceled 50,000 options Canceled on April 15, 2026 under Stock Option Cancellation Agreement

RSUs granted 50,000 RSUs Granted April 15, 2026 under 2020 Stock Incentive Plan

Exercise price of canceled options $4.45 per share Options originally granted September 1, 2025

Shares held after transaction 50,000 shares Common stock directly owned following RSU vesting

Original option expiration September 1, 2030 Expiration date of canceled stock options

Key Terms

Stock Option Cancellation Agreement, restricted share units, contingent right, 2020 Stock Incentive Plan

4 terms

Stock Option Cancellation Agreement financial

"the Issuer canceled, pursuant to that certain Stock Option Cancellation Agreement dated April 15, 2026"

restricted share units financial

"In exchange for the Options, the Reporting Person received 50,000 restricted share units ("RSUs")"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

contingent right financial

"Each RSU represents a contingent right to receive one share of common stock upon vesting"

2020 Stock Incentive Plan financial

"The RSUs were granted pursuant to the applicable award agreement and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did LIXT CFO Peter Stazzone change in his equity compensation?

Peter Stazzone canceled 50,000 stock options and received 50,000 restricted stock units instead. The RSUs were granted on April 15, 2026 and vested immediately, giving him a direct right to 50,000 shares of LIXTE common stock.

Did the LIXT CFO buy or sell LIXT stock in this Form 4 filing?

No open-market buying or selling occurred. The Form 4 shows an internal compensation change, where 50,000 stock options were surrendered to the company and replaced with 50,000 restricted stock units that vested immediately into common shares.

How many LIXT options were canceled in the April 15, 2026 transaction?

50,000 options to purchase LIXTE common stock were canceled under a Stock Option Cancellation Agreement dated April 15, 2026. Those options previously had a $4.45 exercise price and were originally granted on September 1, 2025 with a four-tranche vesting schedule.

What did the LIXT CFO receive for canceling his 50,000 stock options?

He received 50,000 restricted stock units in exchange for canceling the options. Each RSU represents a contingent right to one share of common stock, and all 50,000 RSUs vested immediately on April 15, 2026 under Lixte’s 2020 Stock Incentive Plan.

How many LIXT shares does the CFO hold directly after these Form 4 transactions?

After the April 15, 2026 transactions, Peter Stazzone directly holds 50,000 shares of LIXTE common stock. These shares result from the immediate vesting of 50,000 restricted stock units granted in exchange for the cancellation of an equal number of stock options.

What was the exercise price and vesting schedule of the canceled LIXT options?

The canceled options had a $4.45 exercise price and were set to vest in four 25% tranches. Vesting dates were scheduled for September 1, 2025; December 15, 2025; March 15, 2026; and June 15, 2026 before they were replaced with restricted stock units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/17/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stazzone Peter

(Last) (First) (Middle)

433 PLAZA REAL, SUITE 275

(Street)

BOCA RATON FLORIDA 33432

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LIXTE BIOTECHNOLOGY HOLDINGS, INC. [ LIXT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/15/2026		A		50,000	A	(1)	50,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to Purchase Common Stock	$4.45	04/15/2026		D			50,000	(2)	09/01/2030	Common	50,000	(1)	0	D

Explanation of Responses:

1. On April 15, 2026, the Issuer canceled, pursuant to that certain Stock Option Cancellation Agreement dated April 15, 2026 between the Issuer and the Reporting Person, the 50,000 options (the "Options") granted to the Reporting Person on September 1, 2025. In exchange for the Options, the Reporting Person received 50,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable award agreement dated April 15, 2026 and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 50,000 RSUs vest immediately upon grant.

2. The canceled Options provided for vesting 25% on September 1,2025, 25% on December 15,2025, 25% on March 15,2026, and 25% on June 15,2026.

	/s/ Peter Stazzone	04/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)